Since its inception on March 31, 2023, the Ontario Drug Benefit (ODB) program’s Biosimilar Policy requires eligible Ontarians receiving coverage for select originator biologic drugs to transition to their biosimilar versions. In accordance with the ‘Transition Rule,’ there are defined transition periods, occurring in May and November, during which pharmacists a [...]
This page is only available to members. log in or become a member
